Showing 261-270 of 1641 results for "".
FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
https://practicaldermatology.com/series/dermwire-tv/fda-approves-eli-lillys-ad-drug-ebglyss-lebrikizumab/28645/In this week's DermwireTV, Andrew F. Alexis, MD, Professor of Clinical Dermatology at Weill Cornell Medical College, discusses the newly approved AD drug lebrikizumab; LEO Pharma announces two major regulatory milestones for its chronic hand eczema (CHE) treatment; and the CMO of Arcutis BioteherapuAtopic Dermatitis and Psoriasis: Treatments, Considerations, and What’s Coming
https://practicaldermatology.com/topics/atopic-dermatitis/atopic-dermatitis-and-psoriasis-treatments-considerations-and-whats-coming/24038/Atopic dermatitis (AD) and plaque psoriasis (PsO) are two of the most common cutaneous conditions we treat in dermatology. While these chronic inflammatory disorders have similarities, regarding chronic skin disease burden and impact on quality of life, they may diverge when considering clinical preNew Drug Developments in Dermatology
https://practicaldermatology.com/topics/skin-cancer-photoprotection/new-drug-developments-in-dermatology/19971/Despite the COVID pandemic, the FDA had a nearly record year in drug approvals, says Vinod Nambudiri, MD, MBA, which has translated to new developments in dermatology. He discusses approvals of tirbanibulin 1% ointment for actinic keratoses and clascoterone cream 1% for acne, and how they fit into tThe Microbiome: What Do We Know Now?
https://practicaldermatology.com/topics/atopic-dermatitis/the-microbiome-what-do-we-know-now/23122/Questions and answers about the microbiome and its role in influencing cutaneous health.Biosimilar Recommended; Saunders to Head New Pfizer/Allergan Organization
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-biosimilar-recommended-saunders-to-head-new-pfizer-allergan-organization/18825/An FDA committee has recommended Pfizer's Inflectra, biosimilar to infliximab, developed by Celltrion. Sunbelt Melanoma Trial finds no benefit for IFN in Phase III melanoma. Pfizer/Allergan provides details on structure of new organization and announces leadership, including President and COO BrentPharma Sales 2.0
https://practicaldermatology.com/topics/practice-management/pharma-sales-20/23959/A behind-the-scenes look at how ReachRX aims to transform pharma sales and boost patient access.ASDS: Dr. Munavalli on Combining Lasers and Topicals for Skin Cancer
https://practicaldermatology.com/conferences/asds-2024-annual-meeting/asds-dr-munavalli-combining-lasers-and-topicals-skin-cancer/29151/Girish Munavalli, MD, MHS, FAAD, discusses his lecture on lasers in combination with topical medications in the treatment of skin cancer at the 2024 American Society for Dermatologic Surgery Annual Meeting.ASDS: Dr. Downie on Diversity in Dermatology
https://practicaldermatology.com/conferences/asds-2024-annual-meeting/asds-dr-downie-diversity-dermatology/29154/Jeanine B. Downie, MD, FAAD, discusses survey data on different ethnic groups’ cosmetic preferences and the importance of diversity in dermatology at the 2024 American Society for Dermatologic Surgery Annual Meeting.Maui Derm 2024 and Maui Derm Caribbean: Top Stories, Interviews, and More
https://practicaldermatology.com/conferences/maui-derm-2024/maui-derm-2024-and-maui-derm-caribbean-top-stories-interviews-and-more/24043/The sun was bright, and the science was hot at Maui Derm 2024, held at the Grand Wailea Resort in Maui, Hawaii. From new therapies to innovative techniques to treatments in the pipeline, presenters and attendees were eager to share updates and findings at this popular annual event.Credentialing: Building Confidence and Trust
https://practicaldermatology.com/topics/practice-management/credentialing-building-confidence-and-trust/23498/Tips for training staff to answer questions and use credentialing throughout the patient journey to earn loyalty.